Reached a project cooperation agreement with Neurocrine
November 3, 2025
Source: drugdu
71
On November 3, Yaojie Ankang announced on the Hong Kong Stock Exchange that Neurocrine Biosciences, Inc. ( NASDAQ: 00000)NBIX (“Neurocrine”) has entered into a patent transfer and research collaboration agreement with the Company for the payment of royalties in order to develop NLRP3 inhibitors for the treatment of a variety of diseases.
Under the agreement, Neurocrine is granted exclusive rights outside Greater China to develop, manufacture, and commercialize its NLRP3 inhibitors from the Genecast NLRP3 drug platform, while the Company retains the rights to develop, manufacture, and commercialize NLRP3 inhibitors within Greater China. The Company will be entitled to an upfront payment under the agreement, and may receive further milestone payments related to R&D and sales milestones as Neurocrine's development and commercialization progress. The total potential value of the agreement is US$881.5 million. The agreement further covers research collaboration between the parties to further develop NLRP3-related technologies.
Source: https://finance.eastmoney.com/a/202511033552850633.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
